{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1047.454",
  "meta" : {
    "versionId" : "9",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "Oncology Nursing Society Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2024-06-03"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2016-12-23"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.454",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113762.1.4.1047.454"
    }
  ],
  "version" : "20161223",
  "name" : "NeuropathySymptomsAssessments",
  "title" : "Neuropathy Symptoms Assessments",
  "status" : "retired",
  "experimental" : false,
  "date" : "2016-12-23T01:00:03-05:00",
  "publisher" : "Oncology Nursing Society Steward",
  "description" : "ONS measure set",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: Intended to capture that symptoms of neuropathy have been assessed.),(Data Element Scope: This data element is intended to document that an assessment for chemotherapy induced peripheral neuropathy was completed for the appropriate breast cancer survivor.  Using the Quality Data Model, the element would map to the Assessment category.),(Inclusion Criteria: All persons with cancer in the first year post-breast cancer treatment who received a chemotherapeutic agent associated with the development of chemotherapy induced peripheral neuropathy (CIPN)),(Exclusion Criteria: All persons with cancer in the first year post-breast cancer treatment who did not receive a chemotherapeutic medication associated with the development of CIPN)",
  "compose" : {
    "include" : [
      {
        "system" : "http://loinc.org",
        "concept" : [
          {
            "code" : "62759-6",
            "display" : "PhenX - clinical neuropathy protocol"
          },
          {
            "code" : "62795-0",
            "display" : "PhenX - diabetic peripheral neuropathy protocol"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:41919ee5-80a1-40eb-8c2f-bb0e42b265cb",
    "timestamp" : "2024-06-14T10:31:29-04:00",
    "total" : 2,
    "contains" : [
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "62759-6",
        "display" : "PhenX - clinical neuropathy protocol 130201"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "62795-0",
        "display" : "PhenX - diabetic peripheral neuropathy protocol 140401"
      }
    ]
  }
}
